✦ LIBER ✦

Ribavirin therapeutic drug monitoring: why, when and how?

✍ Scribed by Françoise Stanke-Labesque; Véronique Loustaud-Ratti; Gérard Babany; Marie-Claude Gagnieu; Pierre Marquet; The French Ribavirin Group OPTIRIB

Book ID: 111194689
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 97 KB
Volume: 24
Category: Article
ISSN: 0767-3981
DOI: 10.1111/j.1472-8206.2009.00778.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Transporters and Drug Discovery: Why, Wh

Transporters and Drug Discovery: Why, When, and How

✍ Kim, Richard B. 📂 Article 📅 2006 🏛 American Chemical Society 🌐 English ⚖ 152 KB

Estimating ribavirin plasma exposure: Ge

Estimating ribavirin plasma exposure: Genetics or therapeutic drug monitoring?

✍ D’Avolio, Antonio; Cusato, Jessica; Calcagno, Andrea; Di Perri, Giovanni 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 279 KB

Pre- and posttransplant immunologic moni

Pre- and posttransplant immunologic monitoring: why, when, and how?

✍ M.A Masri; A Stephan; S Barbari; A Rizk; G Kamel 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Patient Monitoring During Gastrointestin

Patient Monitoring During Gastrointestinal Endoscopy: Why, When, and How?

✍ Cohen, Lawrence B. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 218 KB

Intraoperative neurophysiological monito

Intraoperative neurophysiological monitoring in pediatric neurosurgery: why, when, how?

✍ Francesco Sala; Matevž J. Kržan; Vedran Deletis 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 436 KB

Reply to: “Estimating ribavirin plasma e

Reply to: “Estimating ribavirin plasma exposure: Genetics or therapeutic drug monitoring?”

✍ Rau, Monika; Geier, Andreas 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 277 KB